Navigation Links
Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
Date:9/18/2009

SAN FRANCISCO, Sept. 18 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biopharmaceutical company developing a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today announced the Second and final closing of a private placement financing with aggregate gross proceeds of US $5,611,475, exceeding the target of US $5 million.

As previously reported, the net proceeds of the private placement will be used to continue advancing the Company's clinical development programs with the lead product JX-594. Key value creating milestones planned for the next 12 months include completion of a randomized Phase II trial in liver cancer, followed by initiation of a pivotal Phase III trial in liver cancer. In addition, Jennerex plans to complete a Phase I trial in solid cancers (including lung and colorectal), followed by initiation of a Phase II colorectal cancer trial. Proceeds will also be used for manufacturing, general corporate purposes and to augment working capital.

"This Series C was a success due both to continued investment from many of our current Shareholders, as well as support from a number of important new investors. We are particularly pleased to welcome the Ottawa Regional Cancer Foundation as a significant new investor," said David H. Kirn, M.D., President and CEO. "Jennerex and the Foundation share a common vision of extending and preserving the lives of patients with cancer. We also share a common commitment to build on the great strength of biological research and world-class facilities at the Ottawa Hospital Research Institute (OHRI). The Cancer Foundation's participation will further support and extend the scope of joint research and development activities being undertaken in partnership with Jennerex at the OHRI, including expansion of manufacturing and clinical trial activities," said Dr. Kirn.


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Jennerex Closes $5 Million First Tranche of Series C Financing
2. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
3. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
4. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
5. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
6. Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next-Generation Everolimus Stent
7. EAU Completes Approval Process for Electrolyzed Water as Sanitation Process for Industrial Clean-in-Place Application
8. Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
9. ACD Completes the Second Closing of Series A Financing and Initiates Services for Biomarker Validation and Companion Diagnostic Development
10. Pacific Biometrics Completes $4 Million Debt Financing
11. Alexza Stockholders Approve Share Issuance to Symphony Capital and Alexza Completes Acquisition of Symphony Allegro
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , April 27, 2015 ... this release, please scroll to bottom . ... equities: Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX ), ... Pharmaceuticals Corporation (NASDAQ: SNTA ), Spectrum Pharmaceuticals ... (NASDAQ: MDVN ). Free research report on ...
(Date:4/27/2015)... -- SynGen Inc., a company that focuses on the ... and progenitor cells from umbilical cord blood, bone marrow, ... has added three new members to its management team ... focus on product commercialization. Chuck Novak ... and Chief Financial Officer.  Chuck was most recently CFO ...
(Date:4/27/2015)... Massachusetts and HEIDELBERG , ... -- Addresses unmet need in treatment ... Health announced today it has been granted a patent in ... Receptor". This latest patent supports Molecular Health,s discovery that EPHB4 ... to EPO and promotes tumor growth. EPO stimulates the production ...
(Date:4/27/2015)... 27, 2015  MT Services LLC, a Lawsuit ... today that U.S. District Judge Joseph Goodwin ... conference status meeting in hopes to resolve more ... mesh manufacturers who are involved in multidistrict litigations ... been going on for some time, and Judge ...
Breaking Biology Technology:Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 2Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 4Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 5SynGen Inc. Expands Its Management Team 2Molecular Health Gains Patent for Novel Receptor Utilizing Computational Biomarker Discovery Technology 2Transvaginal Mesh Lawsuit News: Another Joint Conference Status Meeting Ordered by Judge to Resolve More than 70K TVM Lawsuits against Several Mesh Manufacturers, Says Lawsuitsettlementnews.com 2Transvaginal Mesh Lawsuit News: Another Joint Conference Status Meeting Ordered by Judge to Resolve More than 70K TVM Lawsuits against Several Mesh Manufacturers, Says Lawsuitsettlementnews.com 3
... towards building a microscopic device that can construct nano ... the peer-reviewed publication, International Journal of Nanomanufacturing from Inderscience ... , In his 1986 book, The Engines of Creation, ... nanotechnology - to create an assembler, a microscopic device, ...
... Year Period, DUBLIN, Calif., April 28 SuperGen ... the first quarter ended,March 31, 2008., Total revenues ... $4.4 million for the same prior year period. Total ... in royalty revenue, compared,with $3.8 million for the same ...
... 28 Sangamo,BioSciences, Inc. (Nasdaq: SGMO ), ... zinc finger DNA-binding proteins (ZFPs) for therapeutic gene,regulation ... G.,Wiggans to the company,s Board of Directors., ... Officer of,Connetics Corporation, a biotechnology company, from 1994, ...
Cached Biology Technology:Are nanobots on their way? 2Are nanobots on their way? 3SuperGen Reports 2008 First Quarter Financial Results 2SuperGen Reports 2008 First Quarter Financial Results 3SuperGen Reports 2008 First Quarter Financial Results 4SuperGen Reports 2008 First Quarter Financial Results 5SuperGen Reports 2008 First Quarter Financial Results 6SuperGen Reports 2008 First Quarter Financial Results 7SuperGen Reports 2008 First Quarter Financial Results 8SuperGen Reports 2008 First Quarter Financial Results 9Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors 2Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors 3Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors 4
(Date:4/2/2015)... Fingerprint Cards (FPC) has received ... the distributor World Peace Industrial Group (WPI), part of ... the major part of the shipments will take place ... smartphone manufacturers in China . The ... communicated revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:3/31/2015)... YORK , March 31, 2015   Guidepoint ... the launch of the Post-Surgical Pain Management TRACKER, part ... products tracking usage trends in the medical device and ... access to data including treatment volumes, market share, and ... the pain associated with joint surgery. The ...
(Date:3/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has ... Global Strategic Business Report" report to their offering. ... in US$ Thousands by the following Segments: Face Biometrics, and Voice ... Canada , Japan , ... East & Africa , and ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... in a way that had never been observed in ... Current Biology, a Cell Press publication. The discoverywhich marks ... to perceive circular polarized light may lend mantis shrimp ... into a new dimension of vision, said Justin Marshall ...
... minerals--mineral nanoparticles--in oceans and rivers, atmosphere and soils, ... new ways of understanding Earth,s workings. Our planet,s ... driven by the properties of these minerals. ... universities in a paper published in this week,s ...
... finches are becoming more common as pets, but the ... includes some of the most exotic creatures on the ... multi-billion dollar enterprise, but expansion of the industry sometimes ... that afflict these unusual animals. The new Manual ...
Cached Biology News:Mantis shrimp vision reveals new way that animals can see 2Mantis shrimp vision reveals new way that animals can see 3'Nanominerals' influence Earth systems from ocean to atmosphere to biosphere 2Veterinarians' guide to hedgehogs, chinchillas and chelonians.....oh, my! 2
Request Info...
Secure-Seal™ spacer, one well, 20 mm diameter, 0.12 mm deep *set of 100*...
Synphilin 1 Immunogen: Synthetic peptide corresponding to residues S(829) L E L N G E K D K D K G R T L Q R T(847) of human Synphilin 1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Request Info...
Biology Products: